Unicorn Capital Partners
Venture capital1 people tracked
Investment thesis
Unicorn Capital Partners is a venture firm founded in December 2019 whose leader previously ran Pharmstandard Ventures and co-founded Inbio Ventures, with a background in biochemistry and biotech R&D. The firm invests in biotechnology, has co-invested alongside investors such as Third Rock Ventures, Pfizer Ventures, and Bessemer, and reports that a number of its portfolio companies have listed on NASDAQ.
Team · 1 people
from the firm's websiteFrequently asked questions
- What sectors does Unicorn Capital Partners focus on?
- Unicorn Capital Partners focuses on Biotech.
Similar investors
8VC is a technology investment firm that builds and invests in ambitious companies across sectors including life sciences, healthcare, manufacturing, enterprise, logistics, and defense.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
B Capital Group is a multi-stage venture capital firm that backs founders across the company-building lifecycle, investing in technology, healthcare, and energy & resilience sectors.